[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637397":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":59,"collaborators":61,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":26,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":26,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":98,"whyStopped":26,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Nanjing Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vericiguat Group","EXPERIMENTAL","Drug: Vericiguat Patients will receive oral vericiguat in addition to standardized perioperative care. Vericiguat will be initiated 3 days before surgery at a dose of 2.5 mg once daily. Postoperatively, upon resumption of enteral nutrition, vericiguat will be continued and gradually up-titrated every 2 weeks based on blood pressure tolerability to 5 mg, and then to a target dose of 10 mg once daily, taken with food, for a total duration of 1 months.",[13],"Drug: Vericiguat",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of Care Group","ACTIVE_COMPARATOR","Standard of Care Group Patients will receive standardized perioperative cardiovascular surgery care alone, without vericiguat or placebo. Standard care includes preoperative preparation, postoperative monitoring, anti-infection, antiplatelet\u002Fanticoagulation, diuretics, beta-blockers, SGLT2 inhibitors, and other symptomatic treatments for heart failure according to current guidelines.",[19],"Drug: Standard of Care Group",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Vericiguat","Patients will receive oral vericiguat in addition to standardized perioperative care. Vericiguat will be initiated 3 days before surgery at a dose of 2.5 mg once daily. Postoperatively, upon resumption of enteral nutrition, vericiguat will be continued and gradually up-titrated every 2 weeks based on blood pressure tolerability to 5 mg, and then to a target dose of 10 mg once daily, taken with food, for a total duration of 1 months.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Patients will receive standardized perioperative cardiovascular surgery care alone, without vericiguat or placebo. Standard care includes preoperative preparation, postoperative monitoring, anti-infection, antiplatelet\u002Fanticoagulation, diuretics, beta-blockers, SGLT2 inhibitors, and other symptomatic treatments for heart failure according to current guidelines.",[15],[31],{"name":32,"affiliation":33,"role":34},"Si-chong Qian, MD","Beijing Anzhen Hospital","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Hong Liu","CONTACT","18801281613","DR.HONGLIU@FOXMAIL.COM",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Zhi Li, MD","02568303101","zhili_cths@163.com",[46],{"facility":47,"status":26,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":26},"The First Affiliated Hospital of Nanjing Medical University","Nanjing","Jiangsu","210029","China","CN",{"type":54,"coordinates":55},"Point",[56,57],118.77778,32.06167,{"lat":57,"lon":56},{"type":34,"investigatorFullName":37,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Investigator of Department of Cardiac Surgery",[62,63,65,68,70,72,74],{"name":33,"class":6},{"name":64,"class":6},"The Affiliated Hospital of Qingdao University",{"name":66,"class":67},"Changzhou First People's Hospital","UNKNOWN",{"name":69,"class":6},"The First Affiliated Hospital of Guangzhou Medical University",{"name":71,"class":6},"The First Affiliated Hospital of Bengbu Medical University",{"name":73,"class":6},"West China Hospital",{"name":75,"class":67},"Shanghai East Hospital, China","100637397","perioperative-vericiguat-in-patients-undergoing-cardiovascular-surgery-100637397",false,"NCT07594509","Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery","A Multicenter, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery","Inclusion Criteria:\n\n* Aged 18 to 80 years, any sex;\n* Scheduled to undergo cardiovascular surgery at the study centers, including coronary artery bypass grafting (CABG), heart valve replacement\u002Frepair, and great vessel surgery;\n* Preoperative evaluation indicates a high risk of heart failure or confirmed cardiac dysfunction;\n* Systolic blood pressure (SBP) \\>= 100 mmHg;\n* Expected to complete the 6-month postoperative follow-up;\n* Signed written informed consent by the patient or their authorized representative.\n\nExclusion Criteria:\n\n* Current use of other sGC stimulators or phosphodiesterase type 5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil);\n* Severe hypotension (symptomatic hypotension or resting SBP \\\u003C 90 mmHg);\n* Severe hepatic or renal dysfunction (Hepatic: Child-Pugh class C, or ALT\u002FAST \\> 3 times the upper limit of normal; Renal: eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m\\^2, or requiring chronic dialysis);\n* Malignant tumors, severe hematological diseases, or severe malnutrition (albumin \\\u003C 25 g\u002FL);\n* Known allergy to vericiguat or placebo components;\n* Pregnant or lactating women, or those planning to become pregnant during the study period;\n* Currently participating in other interventional clinical trials;\n* Moderate to severe cognitive impairment without a fixed guardian, unable to cooperate with treatment and follow-up;\n* Confirmed severe infection, sepsis, or septic shock preoperatively.","ALL","18 Years","80 Years",{"count":87,"type":88},600,"ESTIMATED","INTERVENTIONAL",[91],"NA","The purpose of this study is to evaluate the efficacy and safety of perioperative vericiguat in patients undergoing cardiovascular surgery. Patients at high risk of heart failure or with confirmed cardiac dysfunction will be randomly assigned to receive either vericiguat plus standard of care or standard of care alone. The primary objective is to determine whether perioperative administration of vericiguat can reduce (I) the Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial Injury; (II) Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI), and the incidence of Major Adverse Cardiovascular Events (MACE) within 12 months after surgery.",[94,95],"Cardio Vascular Disease","Cardiopulmonary Bypass",[97],"cardiovascular","NOT_YET_RECRUITING","2026-05-11",{"date":101,"type":102},"2026-05-18","ACTUAL",{"date":104,"type":88},"2026-05-31",{"date":106,"type":88},"2030-12-31",{"name":5,"class":6},1]